medigraphic.com
ISSN 2520-9078 (Electronic)

2022, Number 2

<< Back Next >>

Revista de Ciencias Médicas de la Habana 2022; 29 (2)

Repercussion of risk factors in the prognosis of COVID-19

Blas RCB, Mendieta PMD, Boyeros FE

Language: Spanish
References: 24
Page: 312-323
PDF size: 431.61 Kb.


ABSTRACT

The current pandemics generalized by the new coronavirus, named as severe acute respiratory syndrome coronavirus 2, causes the known disease as COVID-19, it can present several ways with high mortality and worse evolution, in patients with some risk factors. This article is carried out with the objective to explain the theoretical foundations that demonstrate the influence of risk factors in the prognosis of patients with COVID-19. A revision of the literature found in Medline, LILACS, SciELO, Latindex, Medigraphy, Medscape, Science Direct Elsevier and PubMed was performed, as well as in known reports in bulletins of the World Health Organization/ Panamerican Health Organization and INFOMED. 83 articles were reviewed, 24 were selected, Google Scholar searching was used. It is concluded that diabetes mellitus and other risk factors, worsens evolution and increase mortality in patients with COVID-19.


REFERENCES

  1. Zheng Y, Ma Y, Zhang J, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17: 259–60. doi: https://doi.org/10.1038/s41569-020-0360-5

  2. Emami A, Javanmardi F. Prevalence of Underlying Diseases in Hospitalized Patients with COVID-19: a Systematic Review and Meta-Analysis. Arch Acad Emerg Med [Internet]. 2020 [citado 18 Abr 2022];8(1):e35. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096724/

  3. Serra-Valdés M. Las enfermedades crónicas no transmisibles y la pandemia por COVID-19. Revista Finlay [Internet]. 2020 [citado 18 Abr 2022];10(2):[aprox. 10 p.]. Disponible en: http://revfinlay.sld.cu/index.php/finlay/article/view/846

  4. 4.Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020; 43,867–9. doi: https://doi.org/10.1007/s40618-020-01236-2

  5. Longo M, Caruso P, Maiorino, MI, Bellastella G, Giugliano D, Esposito K. Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies. Cardiovasc Diabetol[Internet].2020[citado 18 Abr 2022];19(115): [aprox. 10 p.]. Disponible en: https://cardiab.biomedcentral.com/articles/10.1186/s12933-020-01090-9

  6. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, Qin R, Wang H, et al. Diabetes is a risk factor for the progression and prognosis of COVID ‐19. Diabetes Metab Syndr [Internet]. 2020 [citado 18 Abr 2022];14(4):e3319 Disponible en : https://onlinelibrary.wiley.com/doi/full/10.1002/dmrr.3319

  7. Maddaloni E, Buzzetti R. Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics. Diabetes Metab Res Rev[Internet]. 2020 [citado 18 Abr 2022]; 31;e3321. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228318/

  8. Huang I, Lim MA. Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression. Diabetes Metabolic Syndrome: Clinical Research Reviews [Internet]. 2020 [citado 18 Abr 2022];14(4): 395-403.] Disponible en: https://www.sciencedirect.com/science/article/pii/S1871402120300837

  9. Tay MZ, Poh CM, Rénia L. The trinity of COVID-19: immunity, inflammation and intervention. Nat RevImmunol. 2020; 20: 363–74. doi: https://doi.org/10.1038/s41577-020-0311-8

  10. Serra Valdés MA. COVID-19. De la patogenia a la elevada mortalidad en el adulto mayor y con comorbilidades. Revista Habanera de Ciencias Médicas [Internet]. 2020 [citado 18 Abr 2022];19(3):[aprox. 9 p.]. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3379/2599

  11. Samada Suárez M, Hernández Perera JC, Piñeiro Pérez D. ¿El SARS-C0V-2 puede ser diabetógeno? Boletín Científico del Cimeq [Internet]. 2020 Jul 6[citado 18 Abr 2022];1(16):5. Disponible en: https://files.sld.cu/cimeq/files/2020/06/Bol-CCimeq-2020-1-16-pag5.pdf

  12. Aguilera Batista O, Bruzón Laguna E de la C. Recomendaciones prácticas para el manejo de los pacientes diabéticos con la COVID-19. Boletín Científico del Cimeq [Internet]. 2020 321 [citado 18 Abr 2022];1(12): 4-5. Disponible en: https://files.sld.cu/cimeq/files/2020/05/Bol-CCimeq-2020-1-12-pag-4-5.pdf

  13. Mejía F, Medina C, Cornejo E, Morello E, Vásquez S, Alave J, Schwalb A, Málaga G. Clinical features and prognostic factors related to mortality in hospitalized adult patients with COVID-19 in a public hospital in Lima, Peru [Internet]. SciELO Preprints. 2020 [citado 20 Abr 2022]. Disponible en: https://preprints.scielo.org/index.php/scielo/preprint/view/858

  14. Preciado-Ortiz ME, Sánchez-Reyes K, Álvarez-Zavala M, González-Hernández LA, Ramos-Solano M, Andrade-Villanueva J. Obesidad e infecciones. Revista Médica MD [Internet]. 2018 [citado 18 Abr 2022];9(4): 341-4 Disponible en: https://www.medigraphic.com/pdfs/revmed/md-2018/md184n.pdf

  15. Stefan N, Birkenfeld AL, Schulze MB, Ludwig DS . Obesity and impaired metabolic health in patients with COVID-19. Nat Rev Endocrinol. 2020;16: 341–2. doi: https://doi.org/10.1038/s41574-020-0364-6

  16. Miranda-Garduño LM, Reza-Albarrán A. Obesidad, inflamación y diabetes. Gac Méd Méx [Internet]. 2008 [citado 18 Abr 2022];144(1): [aprox. 14 p.]. Disponible en: https://www.medigraphic.com/pdfs/gaceta/gm-2008/gm081h.pdf

  17. Dietz W, Santos‐Burgoa C .Obesity and its Implications for COVID‐19 Mortality. Obesity[Internet]. 2020[citado 18 Abr 2022]; 28( 6):[aprox. 6 p.]. Disponible en: https://onlinelibrary.wiley.com/doi/full/10.1002/oby.22818

  18. Bell Castillo J, George Carrión W, García Céspedes ME, Delgado Bell E, George Bell MJ. Identification of metabolic syndrome in patients with diabetes mellitus and hypertension. MEDISAN[Internet]. 2017 [citado 18 Abr 2022];21(10): 3038-45. Disponible en: https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=75532

  19. Chen Q, Zheng Z, Zhang C, Zhang X, Wu H, Wang J. Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Zhejiang, China. Infection. 2020; 48: 543–51. doi: https://doi.org/10.1007/s15010-020-01432-5

  20. Valdés Ramos E, Bencosme Rodríguez N. Frecuencia de la hipertensión arterial y su relación con algunas variables clínicas en pacientes con diabetes mellitus tipo 2. Rev Cubana Endocrinol [Internet]. 2009 Dic [citado 18 Abr 2022];20(3):77-88. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1561-29532009000300002

  21. Giralt-Herrera A, Rojas-Velázquez JM, Leiva-Enríquez J. Relación entre COVID-19 e Hipertensión Arterial. Rev Haban Cienc Méd [Internet]. 2020 [citado 18 Abr 2022]; 19(2):e3246. Disponible en: http://www.revhabanera.sld.cu/index.php/rhab/article/view/3246

  22. Infomed. Tema de Salud[Internet]. La Habana: Infomed;© 1999-2022. [citado 18 Abr 2022]. La Hipertensión Arterial podría elevar el riesgo de muerte por COVID-19. Disponible en: https://temas.sld.cu/hipertension/2020/06/12/la-hipertension-arterial-podria-elevar-el-riesgo-de-muerte-por-covid-19/

  23. Ikizler TA, Kliger AS. Minimizing the risk of COVID-19 among patients on dialysis. Nat Rev Nephrol. 2020; 16: 311–13. doi: https://doi.org/10.1038/s41581-020-0280-y

  24. Bender-del-Busto J, León-Castellón R, Mendieta-Pedroso M. Enfermedad cerebrovascular y COVID-19. Anales de la Academia de Ciencias de Cuba [Internet]. 2020 [citado 18 Abr 2022]; 10(2):[aprox. 14 p.]. Disponible en: http://revistaccuba.sld.cu/index.php/revacc/article/view/802




2020     |     www.medigraphic.com